top of page

AbbVie is paying Cologne based DISCO Pharmaceuticals $40M upfront and up to $2.5B more in milestones to discover target pairs on tumors to create and validate AND-gated antibodies against them

2 hours ago
1 min read

As DISCO CEO Mark Manfredi describes, the idea behind AND-gating is that the antibodies only work where both targets, which are either exclusive or enriched on the tumor, are expressed - thus a precision medicine approach meant to target tumors and spare healthy tissue.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro_Logo_2023_Primary-4.png

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page